WAVE LIFE SCIENCES LTD. Cash and Cash Equivalents
WAVE LIFE SCIENCES LTD. (WVE) had Cash and Cash Equivalents of $368.01 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-07-30
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $368.01M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $544.59M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $602.07M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $196.22M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $368.01M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $544.59M 10-Q · filed 2026-04-28 | |
| 2025-12-31 | $602.07M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $196.22M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $208.48M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $243.07M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $302.08M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $310.95M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $153.96M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $180.92M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $200.35M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $139.94M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $172.97M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $207.56M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $88.50M 10-K · filed 2024-03-06 | |
| 2022-09-30 | $96.95M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $123.16M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $61.71M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $150.56M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $123.90M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $143.84M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $148.53M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $184.50M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $216.36M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $216.40M 10-Q · filed 2020-11-09 | $94.05M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $120.95M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $147.16M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $209.01M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $252.91M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $287.57M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $174.82M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $210.49M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $241.43M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $110.49M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $142.50M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $168.46M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $197.39M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $129.48M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $150.29M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $169.01M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $181.76M 10-Q · filed 2017-08-09 | |
| 2016-03-31 | $153.40M 10-Q · filed 2017-05-10 | |
| 2015-12-31 | $161.22M 10-K · filed 2018-03-12 | |
| 2015-09-30 | $66.04M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $7.78M 10-Q · filed 2016-08-15 | |
| 2015-03-31 | $10.96M 10-Q · filed 2016-05-16 | |
| 2014-12-31 | $1.05M 10-K · filed 2018-03-12 | |
| 2014-09-30 | $2.49M 10-Q · filed 2015-12-17 | |
| 2013-12-31 | $439.00K 10-K · filed 2017-03-16 | |
| 2012-12-31 | $379.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |